Methods: Using patient registration database of a university hospital of Iran University of Medical Scicnes, we extracted the data of diagnosed celiac patients. All demographic data, signs
and symptoms and laboratory data including celiac disease serologic tests were collected. All patients had been diagnosed based on Marsh classification following duodenal biopsy. The ethics committee of the Iran University of Medical Science approved the study and informed consents were obtained from all patients after explaining the study aims and protocol. Results: 133 celiac disease patients (80 men) with mean age of 42 were recruited. The most common chief complaint was diarrhea in 57 patients (43%). Constipation, weight loss, abdominal pain, chronic dyspepsia and Reflux were also main complaints in about 6% of patients, separately. 12 patients ABT-263 chemical structure were referred only by chronic fatigue and malaise, whom finally being diagnosed for CD. In 2 patients the diagnosis of CD was made following evaluation of recurrent abortion and in 1 for infertility. Anemia reported in 73% patients besides other symptoms, however it was the only chief complaint
of 22 patients. The main clue for diagnosis of CD in 5 patients was abnormal LFT. Conclusion: Celiac disease in Iran is presented with a wide range of signs and symptoms. The real challenge about celiac disease is to recognize atypical, asymptomatic or Caspase activity oligosymptomatic cases. We recommend thinking about celiac disease in all cases with suspicious signs and symptoms and checking celiac disease serologic tests to prevent late or misdiagnose. Key Word(s): 1. Celiac disease; 2. Iran; Presenting Author: CHEN HUANG Additional Authors: BIN LV, SHUO ZHANG, HONGYI FAN, LU
ZHANG, NING JIANG Corresponding Author: CHEN HUANG, BIN LV Affiliations: selleck screening library First Affiliated Hospital of Zhejiang Chinese Medical University Objective: Data indicate that NSAIDs-induced small bowel injury are less well recognized in the past. In a randomized, open-label, controlled clinical trial with video capsule endoscopy (VCE), we prospectively to evaluate the incidence of small bowel injury in healthy subjects treated with diclofenac and the effect of isinglass on preventing NSAIDs-induced small bowel injury. Methods: We randomly assigned 20 healthy subjects with normal baseline VCEs to A group (isinglass 3 g twice daily plus diclofenac slow-release 75 mg twice daily, n = 10), or B group (diclofenac slow-release 75 mg twice daily, n = 10), all of them with omeprazole 20 mg once daily for gastroprotection for a total of 14 days, then the VCE investigations were repeated. Results: After drug treatment, 18 subjects (7 males and 11 females; mean age 34.1 years; A group: n = 8, B group: n = 10) had increased repeat the VCE investigations above the upper limit of normal. Capsule enteroscopy showed new pathology in 11 subjects (A:4/8, 50%; B:7/10, 70%).